# Consensus checked against original sources: Retatrutide: Clinical Weight Loss and Supply Claims

Cutoff: 12 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## Consensus identifies placebo-controlled phase2 weight efficacy and dose/tolerability.
Original abstract agrees with338randomized adults,24-week primary and48-week secondary weights and high-dose5%responders. This supports trial efficacy, not a modern active-comparator superiority claim. Fulltrial Methods/supplementwere not fully audited. [Original PMID37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/). Access: abstract_metadata.

## Provider reports40-week TRANSCEND-T2D-1 phase3 weight results and completion.
Original abstract confirms537participants and treatment-regimen weight change−11.5%to−15.3%versus−2.6%placebo. Primary endpointisHbA1c and entryBMI≥23; whole-cohort weights do not exactly estimate the preregistered obesity/overweight subset. [Original PMID42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/). Access: abstract_metadata.

## Consensus does not retrieve the named2026TRIUMPH1results and instead cites the2025designpaper.
Original PMID42814954 confirms peer-reviewed29September2026results,2339randomizedparticipants and80-week treatment-regimen weights up to−25.0%versus−3.9%placebo. Provider corpus omission is not absenceofpublication.80weeks is longer-horizon corroboration beyond our registered24–72weeks. IndexedOSA sign inconsistency is flagged without repeatingthatnumber. [Original PMID42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/). Access: abstract_metadata.

## Provider similarly lacks indexedTRIUMPH2resulttext.
Original PMID42810372 confirms1152randomized adults withBMI≥27andT2D, multiple-imputation treatment-regimen weight results at80weeks and tolerability signals. This resultisavailablebeforecutoff; provider gap cannotbe called a researchgap. [Original PMID42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/). Access: abstract_metadata.

## Consensus distinguishes older dulaglutide active comparison from obesity-standard comparator evidence.
Original randomized double-dummy phase2 report confirms36-week retatrutideweight loss beyond dulaglutide1.5mg atdoses≥4mg, but cannot establish superiorityoverobesity-dose semaglutide/tirzepatide. [Original PMID37385280](https://pubmed.ncbi.nlm.nih.gov/37385280/). Access: abstract_metadata.

## Provider suggests appetite modification contributes to weight loss.
Selected original Methods/Results retain self-reportedhigher-dose hunger effects, but satiety/fullness and aggregate appetite-to-weight correlations are oftennull. These are samephase2participants, not a newtrial or proof of receptor-specific mediation. [Original PMID40916752](https://pubmed.ncbi.nlm.nih.gov/40916752/). Access: full_text_partial.

## Consensus describes lipid remodeling andmechanistic humanfollow-up.
Selected originalbodyconfirms post-hoc phase2analyses and exclusionofpost-discontinuation/rescue samples. Inflammationcontrasts are nonsignificant inT2D but somepositive in non-diabetes. Surrogates are not hardcardiovascularoutcomes or independentclinicalcausallines. [Original PMID42608321](https://pubmed.ncbi.nlm.nih.gov/42608321/). Access: full_text_partial.

## Provider reports no direct retatrutide online-vialquality data initscorpus.
Our original class-product testing issemaglutide, notretatrutide, andhighest-risk vendor sampling islimited. Results report upper-bound endotoxinvalues fortwo samples and anelevatedmeasuredvalueforone despiteabstractbroadwording. Suchdataestablishesfailuremodes, not everyretatrutidevialquality. [Original PMID39509151](https://pubmed.ncbi.nlm.nih.gov/39509151/). Access: full_text_partial.

## Provider calls bodycomposition andweight-quality outcomesunderdeveloped.
Original2025retatrutideDXAsubstudyexists andshows higher-dosefat-massreduction, but only103completed bothscans. Leanmassproportions do notprove musclefunction or absenceofsarcopenia; thissamephase2trialdoesnotcreateanindependence line. [Original PMID40609566](https://pubmed.ncbi.nlm.nih.gov/40609566/). Access: abstract_metadata.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.